The Evaluation of the Fetal Fibronectin Test for Prediction of Preterm Delivery in Symptomatic Patients

Journal of Obstetrics and Gynaecology Canada

Volumn 28, Issue 3, 2006, Pages 206-213

  Skoll, Amanda ^a   St Louis, Patrick ^b   Amiri, Neda ^a   Delisle, Marie France ^a   Lalji, Sayrin ^a  

^a CHILDREN S AND WOMEN S HEALTH CENTRE OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

Fetal fibronectin; Prematurity; Preterm labour; Screening

Indexed keywords

FIBRONECTIN; FFN PROTEIN, HUMAN; GLYCOPROTEIN;

ARTICLE; CANADA; CONTROLLED STUDY; FEMALE; FETAL FIBRONECTIN TEST; GESTATIONAL AGE; HUMAN; MEDICAL PROCEDURES; PREDICTION; PREMATURE LABOR; SYMPTOMATOLOGY; TERTIARY CARE CENTER; CHEMISTRY; PREDICTION AND FORECASTING; PREGNANCY; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SINGLE BLIND PROCEDURE; UTERINE CERVIX MUCUS;

CERVIX MUCUS; FEMALE; FIBRONECTINS; GLYCOPROTEINS; HUMANS; OBSTETRIC LABOR, PREMATURE; PREDICTIVE VALUE OF TESTS; PREGNANCY; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; SINGLE-BLIND METHOD;

EID: 34247603274     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)32110-7     Document Type: Article

References (44)

1. Morrison J.C. Preterm birth: a puzzle worth solving. Obstet Gynecol 1990, 76:5S-12S.
2. McCormick M.C. The contribution of low birth weight to infant mortality and childhood morbidity. N Engl J Med 1985, 312:82-90.
3. Hack M., Fanaroff A.A. Outcomes of extremely immature infants: a perinatal dilemma. N Engl J Med 1993, 329:1649-1650.
4. Klam S.L., Leduc L. Management options for preterm labour in Canada. J Obstet Gynaecol Can 2004, 26:339-345.
5. ACOG Practice Bulletin no. 43: management of preterm labor vol 101. Obstet Gynecol 2003, 5:1039-1047.
6. McWhorter J., Carlan S.J., O'Leary T.D., Richichi K., O'Brien W.F. Rofecoxib versus magnesium sulfate to arrest preterm labor: a randomized trial. Obstet Gynecol. 2004, 103:923-930.
7. Smith G.N. What are the realistic expectations of tocolytics?. BJOG 2003, 110:103-106.
8. Canadian Preterm Labor Investigators Group Treatment of preterm labor with the beta-adrenergic agonist ritodrine. N Engl J Med 1992, 327:308-312.
9. Carey J.C., Klebanoff M.A., Hauth J.C., Hillier S.L., Thom E.A., Ernest J.M., et al. Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis: National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. N Engl J Med 2000, 342:534-540.
10. Goldenberg R.L., Thom E., Moawad A.H., Johnson F., Roberts J., Caritis S.N. The preterm prediction study: fetal fibronectin, bacterial vaginosis, and peripartum infection: NICHD Maternal Fetal Medicine Units Network. Obstet Gynecol 1996, 87:656-660.
11. Thorp J.M., Hartmann K.E., Berkman N.D., Carey T.S., Lohr K.N., Gavin N.I., et al. Antibiotic therapy for the treatment of preterm labor: a review of the evidence. Am J Obstet Gynecol. 2002, 186:587-592.
12. Berkman N.D., Thorp J.M., Lohr K.N., Carey T.S., Hartmann K.E., Gavin N.I., et al. Tocolytic treatment for the management of preterm labor: a review of the evidence. Am J Obstet Gynecol 2003, 188:1648-1659.
13. Sanchez-Ramos L., Kaunitz A.M., Gaudier F.L., Delke I. Efficacy of maintenance therapy after acute tocolysis: a meta-analysis. Am J Obstet Gynecol 1999, 181:484-490.
14. Meirowitz N.B., Ananth C.V., Smulian J.C., Vintzileos A.M. Value of maintenance therapy with oral tocolytics: a systematic review. J Matern Fetal Med 1999, 8:177-183.
15. Moutquin J.-M. Preterm births in Canada. Where do we go from here?. JSOGC 1999, 21:12-15.
16. St John E.B., Nelson K.G., Cliver S.P., Bishnoi R.R., Goldenberg R.L. Cost of neonatal care according to gestational age at birth and survival status. Am J Obstet Gynecol 2000, 182:170-175.
17. Lockwood C.J., Senyei A.E., Dische M.R., Casal D., Shah K.D., Thung S.N., et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med 1991, 325:669-674.
18. Feinberg R.F., Kliman H.J., Lockwood C.J. Is oncofetal fibronectin a trophoblast glue for human implantation?. Am J Path 1991, 138:537-543.
19. Lockwood C.J., Wein R., Lapinski R., Casal D., Berkowitz G., Alvarez M., et al. The presence of cervical and vaginal fetal fibronectin predicts preterm delivery in an inner-city obstetric population. Am J Obstet Gynecol 1993, 169:798-804.
20. Faron G., Boulvain M., Irion O., Bernard P.M., Fraser W.D. Prediction of preterm delivery by fetal fibronectin: A meta-analysis. Obstet Gynecol 1998, 92:153-158.
21. Goldenberg R.L., Mercer B.M., Iams J.D., Moawad A.H., Meis P.J., Das A., et al. The preterm prediction study: patterns of cervicovaginal fetal fibronectin as predictors of spontaneous preterm delivery. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1997, 177:8-12.
22. Hellemans P., Gerris J., Verdonk P. Fetal fibronectin detection for prediction of preterm birth in low risk women. Br J Obstet Gynaecol 1995, 102:207-212.
23. Joeffe G.M., Jacques D., Bermis-Heys R., Burton R., Skram B., Shelburne P. Impact of the fetal fibronectin assay on admission for preterm labor. Am J Obstet Gynecol 1999, 180:581-586.
24. Peaceman A.M., Andrews W.W., Thorp J.M., Cliver S.P., Lukes A., Iams J.D., et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am J Obstet Gynecol 1997, 177:13-18.
25. Revah A., Hanna M.E., Sue-A-Quan A.K. Fetal fibronectin as a predictor of preterm birth: an overview. Am J Perin 1998, 15:621.
26. Roman A.S., Koklanaris N., Paidas M.J., Mulholland J., Levitz M., Rebarber A. "Blind" vaginal fetal fibronectin as a predictor of spontaneous preterm delivery. Obstet Gynecol 2005, 105:285-289.
27. Roman A.S., Rebarber A., Lipkind H., Mulholland J., Minior V., Roshan D. Vaginal fetal fibronectin as a predictor of spontaneous preterm delivery after multifetal pregnancy reduction. Am J Obstet Gynecol 2004, 190:142-146.
28. Romero R., Espinoza J., Chaiworapongsa T., Kalache K. Infection and prematurity and the role of preventive strategies. Semin Neonatol 2002, 7:259-274.
29. Goncalves L.F., Chaiworapongsa T., Romero R. Intrauterine infection and prematurity. Ment Retard Dev Disabil Res Rev 2002, 8:3-13.
30. Simhan H.N., Caritis S.N., Krohn M.A., Hillier S.L. The vaginal inflammatory milieu and the risk of early premature preterm rupture of membranes. Am J Obstet Gynecol 2005, 192:213-218.
31. Locksmith G., Duff P. Infection, antibiotics, and preterm delivery. Semin Perinatol 2001, 25:295-309.
32. Sherman D.J., Tovbin J., Lazarovich T., Avrech O., Reif R., Hoffmann S., et al. Chorioamnionitis caused by gram-negative bacteria as an etiologic factor in preterm birth. Eur J Clin Microbiol Infect Dis 1997, 16:417-423.
33. Ascarelli M.H., Morrison J.C. Use of fetal fibronectin in clinical practice. Obstet Gynecol Surv 1997, 52:S1-S12.
34. Dept of Health and Human Services (US) [DHHS] STD Surveillance, 2003 [report on the Internet] 2003, Centers for Disease Control and Prevention [CDC], Atlanta (GA), [cited 2005 Jun 13]. Available at:. http://www.cdc.gov/std/stats/toc2003.htm.
35. BC Center for Disease Control (CAN) [BCCDC] STD/AIDS Control, 2003 [report on the Internet] 2003, Chlamydia Statistics, Vancouver (BC), [cited 2005 Jun 13]. Available at:. http://www.bccdc.org/downloads/pdf/std/reports/chlamydia%202003.pdf.
36. BC Center for Disease Control (CAN) [BCCDC] STD/AIDS Control, 2003 [report on the Internet] 2003, Gonorrhea Statistics, Vancouver (BC), [cite 2005 Jun 13]. Available at:. http://www.bccdc.org/downloads/pdf/std/reports/gonorrhea%202003.pdf.
37. Andersen H.F. Use of fetal fibronectin in women at risk for preterm delivery. Clin Obstet Gynecol 2000, 43:746-758.
38. Crane J.M., Armson B.A., Dodds L., Feinberg R.F., Kennedy W., Kirkland S. Risk scoring, fetal fibronectin, and bacterial vaginosis to predict preterm delivery. Obstet Gynecol 1999, 93:517-522.
39. Effect of corticosteroids for fetal maturation on perinatal outcomes. NIH Consensus Statement Feb 28-March 2, 194: 12(2):1-24.
40. Gibbs R.S., Romero R., Hillier S.L., Eschenbach D.A., Sweet R.L. A review of premature birth and subclinical infection. Am J Obstet Gynecol 1992, 166:1515-1528.
41. Joffe G.M., Jacques D., Bemis-Hayes R., Burton R., Skram B., Shelburne P. Impact of the fetal fibronectin assay on admissions for preterm labor. Am J Obstet Gynecol 1999, 180:581-586.
42. Giles W., Bisits A., Knox M., Madsen G., Smith R. The effect of fetal fibronectin testing on admissions to a tertiary maternal fetal medicine unit and cost savings. Am J Obstet Gynecol 2000, 182:439-442.
43. Lowe M.P., Zimmerman B., Hansen W. Prospective randomized controlled trial of fetal fibronectin on preterm labor management in a tertiary care center. Am J Obstet Gynecol 2004, 190:358-362.
44. Grobman W.A., Welshman E.E., Calhoun E.A. Does fetal fibronectin use in the diagnosis of preterm labor affect physician behavior and health care costs? A randomized trial. Am J Obstet Gynecol 2004, 191:235-240.